Pavidon LLC

Pavidon LLC is developing a biologic pharmaceutical product as an adjunctive therapy to facilitate vitrectomy surgery.

The product, dispase, is a bacterial neutral protease shown to specifically cleave Type IV collagen and fibronectin, two of the more prevalent structural protein anchors found at the junction of the vitreous and the retina.

More than 600,000 vitrectomies are performed worldwide each year. During vitrectomy surgery, the vitreous is removed and these protein anchors are mechanically cleaved. This mechanical cleavage often leads to detached retinas, macular holes, or other complications.

Dispase works to pharmacologically cleave these proteins, potentially reducing the risks to the patient. Dispase has been shown in large animal models to induce a posterior vitreous detachment in a dose-dependent manner.

Pavidon is conducting preclinical tests of dispase and plans to file an IND toward the beginning of 2005. RCT and RegenaSight Inc. formed Pavidon in December 2003 to develop this technology

Inventors/Founders

Lucian V. Del Priore, M.D., Ph.D., Henry J. Kaplan, M.D., and Tongalp H. Tezel, M.D.

Pavdon Contact

Jay Foust, RCT Director & Pavidon President